[go: up one dir, main page]

FI963185A - Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi - Google Patents

Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi Download PDF

Info

Publication number
FI963185A
FI963185A FI963185A FI963185A FI963185A FI 963185 A FI963185 A FI 963185A FI 963185 A FI963185 A FI 963185A FI 963185 A FI963185 A FI 963185A FI 963185 A FI963185 A FI 963185A
Authority
FI
Finland
Prior art keywords
preparation
materials
methods
hematopoietic protein
hematopoietic
Prior art date
Application number
FI963185A
Other languages
English (en)
Swedish (sv)
Other versions
FI963185A0 (fi
Inventor
Richard D Holly
Si Lok
Donald C Foster
Frederick S Hagen
Kenneth Kaushansky
Joseph L Kuijper
Catherine E Lofton-Day
Pieter J Oort
Steven K Burkhead
Original Assignee
Zymogenetics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Univ Washington filed Critical Zymogenetics Inc
Publication of FI963185A0 publication Critical patent/FI963185A0/fi
Publication of FI963185A publication Critical patent/FI963185A/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
FI963185A 1994-02-14 1996-08-14 Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi FI963185A (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19602594A 1994-02-14 1994-02-14
US20319794A 1994-02-25 1994-02-25
US21520394A 1994-03-21 1994-03-21
US25249194A 1994-06-01 1994-06-01
PCT/US1994/008806 WO1995021920A1 (en) 1994-02-14 1994-08-05 Hematopoietic protein and materials and methods for making it

Publications (2)

Publication Number Publication Date
FI963185A0 FI963185A0 (fi) 1996-08-14
FI963185A true FI963185A (fi) 1996-08-14

Family

ID=27498094

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963185A FI963185A (fi) 1994-02-14 1996-08-14 Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi

Country Status (17)

Country Link
US (1) US5989537A (fi)
EP (1) EP0745125A1 (fi)
JP (1) JPH09508797A (fi)
KR (1) KR100289201B1 (fi)
CN (1) CN1148408A (fi)
AU (1) AU691828B2 (fi)
BG (1) BG63508B1 (fi)
BR (1) BR9408534A (fi)
CA (1) CA2183266A1 (fi)
CZ (1) CZ221496A3 (fi)
FI (1) FI963185A (fi)
HU (1) HUT75359A (fi)
NO (1) NO963371L (fi)
NZ (1) NZ271230A (fi)
PL (1) PL178384B1 (fi)
SK (1) SK100896A3 (fi)
WO (1) WO1995021920A1 (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
KR100303810B1 (ko) * 1994-03-31 2001-12-01 스티븐 엠. 오드리 거핵구성장및분화를자극하기위한조성물및방법
TW387940B (en) * 1995-01-17 2000-04-21 Kirin Brewery Anti-tpo monodonal antibody
EP0807181A1 (en) 1995-02-03 1997-11-19 G.D. Searle & Co. NOVEL c-MPL LIGANDS
US5696250A (en) 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PE7898A1 (es) 1995-06-07 1998-03-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
AU722759B2 (en) * 1995-10-05 2000-08-10 G.D. Searle & Co. Novel C-MPL receptor agonists
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6884419B1 (en) * 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1137773T3 (da) 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
DE60135393D1 (de) 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
EP1336846A1 (en) * 2002-02-13 2003-08-20 Procorde GmbH Method for generating recombinant human platelets for identifying therapeutic target proteins
US20040076617A1 (en) * 2002-03-18 2004-04-22 Lieber Jonathan Gregory Method for production of neutrophils and uses therefor
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
DE10227611A1 (de) * 2002-06-20 2004-01-15 Bionethos Holding Gmbh Verfahren und Vorrichtung zur Vermehrung und Differenzierung von Zellen in Anwesenheit von Wachstumsfaktoren und einer biologischen Matrix oder Trägerstruktur
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
EP2319528B8 (en) 2002-09-18 2020-03-04 Janssen Pharmaceuticals, Inc. Methods of increasing platelet and hematopoietic stem cell production
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
PL2251353T3 (pl) 2003-08-07 2013-08-30 Zymogenetics Inc Homogenne preparaty IL-29
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
NZ545455A (en) 2003-08-28 2009-02-28 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2140875A1 (en) * 2003-10-24 2010-01-06 Nora, LLC Compositions and methods for healthy pregnancy
BRPI0418326A (pt) 2003-12-30 2007-05-02 Bionethos Holding Gmbh método de regeneração de tecidos
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
CN101087874A (zh) 2004-10-25 2007-12-12 塞勒兰特治疗公司 增殖骨髓细胞群体的方法及其应用
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
CA2840407A1 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20110294733A1 (en) 2009-01-20 2011-12-01 Hanall Biopharma Co., Ltd. Modified human thrombopoietin polypeptide fragment and manufacturing method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets

Also Published As

Publication number Publication date
KR100289201B1 (ko) 2001-05-02
BR9408534A (pt) 1997-08-05
SK100896A3 (en) 1997-10-08
WO1995021920A1 (en) 1995-08-17
HU9602224D0 (en) 1996-10-28
PL178384B1 (pl) 2000-04-28
FI963185A0 (fi) 1996-08-14
CN1148408A (zh) 1997-04-23
HUT75359A (en) 1997-05-28
CZ221496A3 (en) 1997-07-16
US5989537A (en) 1999-11-23
EP0745125A1 (en) 1996-12-04
PL315914A1 (en) 1996-12-09
NO963371L (no) 1996-10-11
CA2183266A1 (en) 1995-08-17
NO963371D0 (no) 1996-08-13
AU691828B2 (en) 1998-05-28
BG100771A (en) 1997-08-29
NZ271230A (en) 1998-03-25
JPH09508797A (ja) 1997-09-09
AU7481094A (en) 1995-08-29
BG63508B1 (bg) 2002-03-29

Similar Documents

Publication Publication Date Title
FI963185A (fi) Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi
FI972165A (fi) Aerogeelipitoinen komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö
FI941137A (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
FI935485A (fi) PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
BR9707501A (pt) Composto composição farmacêutica e uso do composto
FI971495A0 (fi) Vaahdonestokoostumus ja sen käyttömenetelmä
BR9610109A (pt) Fecho e uso mesmo
FI962844A0 (fi) T-soluantigeenireseptorin V-alueen proteiineja ja menetelmiä niiden valmistamiseksi
BR9707812A (pt) Composto composto farmacêutica e uso do composto
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
BR9707808A (pt) Composto composição farmacêutica e uso do composto
AU7422496A (en) NM03 antibody materials and methods
FI952229A (fi) Kuumuutta kestävä hiusvalmiste ja menetelmä sen käyttämiseksi
BR9509688A (pt) Composto e composição farmacêutica
FI964267A (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
FI970097A (fi) Proteiinit, jotka ovat peräisin nisäkkäiden maksasta ja niiden käyttö onkologiassa
DK0826679T3 (da) Naphthylforbindelser og -præparater
FI971376A0 (fi) Trofinin och trofininmedlande proteiner
FI955123A (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi
FI953391A (fi) Komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö
FI940403A (fi) Elliptisiinijohdannainen ja menetelmä sen valmistamiseksi
FI960706A0 (fi) Uusi proteiini ja menetelmiä proteiinin valmistamiseksi
EE9500029A (et) Farmatseutiline pihustatav kompositsioon ja selle saamise meetod